107115-25-3

Basic information

• Product Name: Benzaldehyde, 4-(3-hydroxypropoxy)-3-methoxy-
• CAS NO: 107115-25-3
• Molecular Formula: C11H14O4
• Molecular Weight: 210.23
• Mol File: 107115-25-3.mol

Chemical Properties

• CAS DataBase Reference: Benzaldehyde, 4-(3-hydroxypropoxy)-3-methoxy-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzaldehyde, 4-(3-hydroxypropoxy)-3-methoxy-(107115-25-3)
• EPA Substance Registry System: Benzaldehyde, 4-(3-hydroxypropoxy)-3-methoxy-(107115-25-3)

Safety Data

• Hazardous Substances Data: 107115-25-3(Hazardous Substances Data)

Upstream product

• 627-30-5 1-chloro-3-hydroxypropane 
• 627-32-7 1-iodopropan-3-ol 
• 121-33-5 vanillin 
• 627-18-9 1-bromo-3-propanol 

Downstream Products

• 1255526-68-1 N'-(4-(3-hydroxypropoxy)-3-methoxybenzylidene)-3-(3-methyl-1H-indol-1-yl)propanehydrazide 
• 656810-14-9 3-methoxy-4-[3-(3-phenoxypropoxy)propoxy]benzaldehyde 
• 656810-10-5 3-methoxy-4-[3-(4-toluenesulfonyl)propoxy]benzaldehyde 
• 550356-12-2 3-(4-formyl-2-methoxy-5-nitrophenoxy)propionic acid 

Relevant articles and documents

Bisferrocene-containing ionic liquid supported on silica coated Fe3O4: A novel nanomagnetic catalyst for the synthesis of dihydropyrano[2,3-c]coumarin derivatives

Nanomagnetic bisferrocene-containing ionic liquid supported on silica coated Fe3O4 (Fe3O4@SiO2@imidazol-bisFc[HCO3]) as a novel heterogeneous catalyst was synthesized and the structure and

HYDRAZONE COMPOUNDS AND THEIR USE

The present invention relates to hydrazone compounds of Formula I: (I) and pharmaceutically acceptable salts and stereoisomers thereof, wherein R1, R2, R3, R4, L1, and L2 are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula I as inhibitors of TRPM5 protein.

Unsymmetrical DNA cross-linking agents: Combination of the CBI and PBD pharmacophores

A set of 10 compounds, each combining the seco-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one (seco-CBI) and pyrrolo [2,1-c] [1,4] benzodiazepine (PBD) pharmacophores, was designed and prepared. These compounds were anticipated to cross-link between N3 of adenine and N2 of guanine in the minor groove of DNA. The compounds, which differ in the chain length separating the two alkylation subunits, and the configuration of the CBI portion, showed great variation in cellular toxicity (over 4 orders of magnitude in a cell line panel) with the most potent example exhibiting IC50S in the pM range. Cytotoxicity correlated with the ability of the compounds to cross-link naked DNA. Cross-linking was also observed in living cells, at much lower concentrations than for a related symmetrical PBD dimer. A thermal cleavage assay was used to assess sequence selectivity, demonstrating that the CBI portion controlled the alkylation sites, while the PBD substituent increased the overall efficiency of alkylation. Several compounds were tested for in vivo activity using a tumor growth delay assay against WiDr human colon carcinoma xenografts, with one compound (the most cytotoxic and most efficient cross-linker) showing a statistically significant increase in survival time following a single iv dose.

Synthesis of Oligonucleotides Containing 3'-Alkyl Carboxylic Acids Using Universal, Photolabile Solid Phase Synthesis Supports

The synthesis and application of photolabile supports for solid phase oligonucleotide syntheses that release oligonucleotides containing 3'-alkyl carboxylic acids is described.The carboxylic acid functionality is revealed without removing any other protrc